Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIR... ( Safety and Efficacy Rates in Patients...)

HOME >> MEDICINE >> NEWS

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIRIT V Study

Date:5/21/2009

Safety and Efficacy Rates in Patients with Challenging Anatomy Consistent with Superior Results from Randomized Clinical Trials

BARCELONA, Spain, May 21 /PRNewswire-FirstCall/ -- New data presented today at EuroPCR from an international, post-approval, single-arm study show that Abbott's market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated low rates of repeat procedure (target lesion revascularization), stent thrombosis and major adverse cardiac events (MACE) in a complex patient population. In the SPIRIT V (five) study, XIENCE V (vee) demonstrated a very low 1.8 percent rate of target lesion revascularization (TLR), a 0.7 percent rate of stent thrombosis and a 5.1 percent rate of MACE at one year. MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction attributed to the target vessel), and TLR driven by lack of blood supply. The SPIRIT V study evaluated XIENCE V in a diverse, "real world" population of patients and lesion types, including diabetics, patients with multi-vessel disease and patients with highly complex lesions.

"The data from real-world studies are valuable because they reflect a broad patient population that is more representative of the spectrum of disease seen in a typical interventional cardiology practice," said Eberhard Grube, M.D., chief, Department of Cardiology and Angiology, Heart Center Sieburg in Germany and principal investigator of the SPIRIT V study. "The one-year results from SPIRIT V indicate that even in a patient population with a high percentage of complex lesions, XIENCE V exhibits remarkably low event rates, similar to what was seen when XIENCE V was studied in controlled, randomized SPIRIT studies."

SPIRIT V is an international, post-approval study of 2,663 patients. Approximately 100 clinical sites throughout Europe, Asia-Pacific and Canada are
'/>"/>

2

GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
2. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
3. Spirit II explores long-term performance of XIENCE V stent
4. Abbott Receives CE Mark for Smaller-Size XIENCE(TM) V Drug Eluting Stent
5. FDA Advisory Committee Recommends Approval of Abbotts XIENCE(TM) V Drug Eluting Stent System
6. Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
7. Ted Karkus Admits to Financial Relationship With Dr. Richard A. Rosenbloom; Demonstrates Pattern of Improper Influence, Unethical Behavior, Falsification and Distortion; Company Questions What Else Karkus May Be Hiding From Shareholders
8. Siemens Demonstrates Groundbreaking Approach to Stroke Diagnosis at ASNR 2009
9. Concord Coalition Says New Trustees Report Demonstrates the Importance of Health Care Cost Control
10. Ben-Gurion U of the Negev study demonstrates link between appetite and elderly mortality
11. New Research Demonstrates that Wild Blueberries May Support Cardiovascular Health

Post Your Comments:

Abbott's XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, 'Real World' Patients in SPIR...( Safety and Efficacy Rates in Patients...),Health